Theravance Biopharma Inc. (NASDAQ:TBPH)’s share price was down 9.2% during mid-day trading on Wednesday . The stock traded as low as $24.26 and last traded at $24.75, with a volume of 321,365 shares changing hands. The stock had previously closed at $27.26.

Several equities analysts have recently issued reports on TBPH shares. Guggenheim started coverage on shares of Theravance Biopharma in a report on Monday, June 20th. They set a “buy” rating and a $30.00 price objective on the stock. Leerink Swann restated a “buy” rating on shares of Theravance Biopharma in a report on Friday, June 10th. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a report on Tuesday, July 12th. Finally, Bank of America Corp. downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $24.75.

The company’s 50 day moving average price is $23.25 and its 200 day moving average price is $20.09. The stock’s market cap is $1.17 billion.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.14. The company earned $18.40 million during the quarter, compared to the consensus estimate of $18.69 million. Equities research analysts expect that Theravance Biopharma Inc. will post ($4.24) EPS for the current year.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.